Wendy Perrow, Mba Email & Phone Number

Baltimore, Maryland, United States

Baltimore, Maryland

Princeton Capital Advisors is a global independent advisory firm that provides innovative, unconflicted and fact-based strategic advice to a diverse client base on many of their most important financial, investment and transactional decisions.

Atlanta, Georgia, United States

Women founded and led biomedical company with an unwavering commitment to develop novel solutions for women worldwide. First-of-its-kind solutions for infertility and permanent birth control addressing multi-billion dollar market opportunities.

Baltimore, Maryland, United States

• AsclepiX Therapeutics is focused on transforming the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies which may empower patients and families around the world.
• Raised $21 Million via non-dilutive and private investor funding and brought in the Venture Capital firm Xontogeny / Perceptive for the $35M Series A investment. Negotiated exclusive license from Johns Hopkins.
• Spearheaded innovative formulation of new products in-house and global GMP manufacturing of AXT107. Championed small high-performing team to progress three novel products from concept to pre-clinical studies.

Baltimore, MD

• Alba Therapeutics, Inc. Baltimore, MDStart-up clinical-stage Biotechnology Company developing novel therapeutics for autoimmune and gastrointestinal diseases.Chief Executive Officer
• Recruited to lead business development, manage pharmaceutical alliances, create marketing and branding strategies for clinical trials. Closed Licensing Deal for Phase III Asset
• Raised and managed funding from VC investors and pharmaceutical partnerships. Negotiated term sheets for licensing and option agreements. Closed deal with Innovate Biopharmaceuticals, Inc. now 9 Meters Biopharma.
• Promoted to CEO in 2011, raised $31 Million up-front to fund Phase 2b clinical trial, spearheaded GMP manufacturing, development of CeD PRO for primary endpoint. Trial was over-enrolled with 342 patients with celiac.

Gaithersburg, Maryland

• Sigma-Tau Pharmaceuticals, Inc. Gaithersburg, MDClinical-stage Biotechnology Company developing novel therapeutics for Orphan and Rare Diseases.VP Business Development, Marketing & Sales
• Transitioned company to new Orphan drug and rare disease corporate strategy and structure. Established solid procedures, novel corporate branding, recruited the U.S. oncology sales team.
• Spearheaded business development and identified and in-licensed three late stage products Cystaran®, Defitelio®, and Eurartesim® and created their global strategy and pre-marketing campaigns.
• Drove estimated market value by 515%, from $122 Million to $750 Million in 3 years. Created marketing and sales plans for approved products in oncology, biologics, rare diseases, and kidney disease.

• Merck & Co., Inc. Whitehouse Station, NJGlobal Marketing Associate Director (Multiple roles)
• Led launch and managed global marketing for 1st ARB Cozaar® & Hyzaar® and doubled sales in 2 years to $3.1 Billion annual revenue. Spearheaded 2 new indication launches with RENAAL for renal protection and LIIFE for.
• Drove sales 51% to $769 Million in 2000 and accountable for U.S. marketing for Cozaar® and Hyzaar®. Managed market research, regulatory, research, manufacturing, public affairs, investor relations, and KOL advocate.
• Led U.S. launch for Cozaar® and Hyzaar®, generating $507 Million in sales in 1998. Coordinated core marketing promotion of product line and managed a promotional budget of $96M. Successfully led partnership with Merck.
• Directed global launch of chickenpox vaccine Varivax®, led DTC campaign, obtained $500M in sales post launch, began Phase III clinical work on Zostavax® for shingles. Led the global marketing team for Varivax®, M-M-R®.
• Directed U.S. launch of Zocor® marketing programs, including “Targeted Resource Blitz-Zocor” with a $56,000 budget, increasing sales by $10 Million in five months post launch, leading to $5.6 Billion yearly revenue..